NLS Acquisition

ADDvise Group has entered into a share purchase agreement with the owner of Axelerist regarding the acquisition of all shares of Axelerist. Closing of the acquisition takes place today, Nov 22 2023. Axelerist Axelerist, based in Yorktown Heights, New York, is a leading provider of tailored rental and purchase solutions of MedTech- and laboratory equipment […]

Vironova BioAnalytics has announced its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the participation of Accord Investment Partners and Venture Targeter AB. Following the completion of the acquisition, the company will be renamed and rebranded as QuTEM. “We are excited to join forces with these new partners to […]

AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the […]

Thermo Fisher Scientific and Olink Holding have announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for USD 26.00 per common share in cash, representing USD 26.00 per American Depositary Share (ADS) in cash. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common […]

The Icelandic digital health company has acquired aidhere, a developer of prescription digital therapeutics based in Germany. The acquisition strengthens Sidekick Health’s digital health offering to patients and partners with this leading prescription digital therapeutics (PDT) company, it states. aidhere brings with it zanadio, that has fulfilled over 50,000 prescriptions and is recognized within Germany’s […]

Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences for up to USD 1.3 billion. “Hypertension is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease and premature death,” says Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “With its expected benefit-risk profile, […]